Zota Health Care defends board structure against proxy advisory AGAINST vote

Director Flagged GovernanceManagement Changes View source PDF Explain this filing

ZOTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹1300.20

prior close

₹1317.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+3.9% vs market

Pharmaceuticals peers, median of 174sector-0.4%+4.7% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

+0.5

15m

+1.7

30m

+6.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+0.4+3.9-0.4+4.7

Next day

+7.0+1.7+5.3+0.3+6.7

+3.1+0.2+2.9-0.4+3.4

+3.4+0.5+2.9-0.4+3.9

+1.6-1.1+2.7-1.6+3.3

-0.7-0.1-0.6-0.7+0.0

-3.6-1.6-2.0-2.6-1.0

15d

+9.3-1.4+10.7-4.7+14.0

-2.9-7.4+4.5-8.7+5.8

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zota Health Care responds to proxy firm IiAS which recommended AGAINST 4 AGM resolutions: re-appointment of Managing Director, remuneration to Non-Executive Chairman and promoter directors, related party transactions, and material transactions with 87.78% subsidiary Everyday Herbal Beauty Care. Company defends 5 founder-promoter directors with 30 plus years experience, capped remuneration at Rs 12 crores aggregate till FY30, and cites 83.86 percent YoY revenue growth in FY26.

Likely market impact

Shareholders face a contested vote at Sept 28 AGM; proxy firm flags excessive promoter directors while company cites 83.86 percent revenue growth.